|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Bayer |
|---|---|
| Information provided by: | Bayer |
| ClinicalTrials.gov Identifier: | NCT00377793 |
Purpose
This trial is to provide additional important information on the impact of the treatment of the man its ED with vardenafil on partnership. This study is being run at up to 50 study centers in Europe and South Africa to evaluate the use of vardenafil in adult men with erectile dysfunction (often called impotence), and their female partner's sexual quality of life. Many men experience occasional erectile problems during their lives. However, when this becomes a continued problem, it can affect both the man and his female partner. The causes of erectile dysfunction are varied and may be due to physiological or emotional reasons. This study is designed to 1) study the effectiveness and safety of vardenafil, and 2) show whether treating a man its erectile dysfunction with vardenafil will improve his female partner its sexual quality of life. The second part (week 12) of the study (Educational program) a subgroup of subjects/couples, approximately 50% of the randomized subjects, will receive an educational program concerning ED in the from of a DVD.
| Condition | Intervention | Phase |
|---|---|---|
|
Sexual Dysfunction Male Erectile Dysfunction |
Drug: Levitra (Vardenafil, BAY38-9456) Drug: Placebo |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Randomized, Double Blind, Parallel Group Study of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction and Their Female Partners Sexual Quality of Life. PARTNER II |
| Enrollment: | 353 |
| Study Start Date: | July 2006 |
| Study Completion Date: | August 2007 |
| Arms | Assigned Interventions |
|---|---|
| Arm 1: Experimental | Drug: Levitra (Vardenafil, BAY38-9456) |
| Arm 2: Placebo Comparator | Drug: Placebo |
Eligibility| Ages Eligible for Study: | 18 Years to 64 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Inclusion Criteria: Partner
Exclusion Criteria:
Exclusion criteria: Partner
Contacts and Locations
Hide Study Locations| Belgium | |
| LIEGE, Belgium, 4000 | |
| BRUXELLES - BRUSSEL, Belgium, 1000 | |
| GENK, Belgium, 3600 | |
| ROESELARE, Belgium, 8800 | |
| LEUVEN, Belgium, 3000 | |
| France | |
| TOULOUSE, France, 31000 | |
| MARSEILLE, France, 13009 | |
| LILLE, France, 59000 | |
| PARIS, France, 75009 | |
| LA ROCHELLE, France, 17000 | |
| MARSEILLE, France, 13275 | |
| MONT-DE-MARSAN, France, 40000 | |
| LYON, France, 69000 | |
| Germany, Hamburg / 287 | |
| Hamburg, Hamburg / 287, Germany, 20354 | |
| Hamburg, Hamburg / 287, Germany, 22177 | |
| Hamburg, Hamburg / 287, Germany, 20251 | |
| Germany, Niedersachsen / 291 | |
| Hannover, Niedersachsen / 291, Germany, 30625 | |
| Germany, Nordrhein-Westfalen / 325 | |
| Brühl, Nordrhein-Westfalen / 325, Germany, 50321 | |
| Germany, Nordrhein-Westfalen / 481 | |
| Mülheim, Nordrhein-Westfalen / 481, Germany, 45468 | |
| Germany, Nordrhein-Westfalen / 616 | |
| Wuppertal, Nordrhein-Westfalen / 616, Germany, 42103 | |
| Germany, Sachsen / 313 | |
| Leisnig, Sachsen / 313, Germany, 04703 | |
| Dresden, Sachsen / 313, Germany, 01129 | |
| Leipzig, Sachsen / 313, Germany, 04105 | |
| Bautzen, Sachsen / 313, Germany, 02625 | |
| Meißen, Sachsen / 313, Germany, 01662 | |
| Germany, Schleswig-Holstein / 306 | |
| Wahlstedt, Schleswig-Holstein / 306, Germany, 23812 | |
| Italy | |
| Milano, Italy, 20132 | |
| Roma, Italy, 00155 | |
| Bergamo, Italy, 24128 | |
| Napoli, Italy, 80131 | |
| Firenze, Italy, 50139 | |
| Netherlands | |
| NIJVERDAL, Netherlands, 7442 LS | |
| ARNHEM, Netherlands, 6836 BH | |
| ENSCHEDE, Netherlands, 7511 JX | |
| DEVENTER, Netherlands, 7415 EH | |
| South Africa, Free State | |
| Bloemfontein, Free State, South Africa, 9324 | |
| South Africa, Gauteng | |
| Johannesburg, Gauteng, South Africa, 2090 | |
| South Africa, Kwa Zulu-Natal | |
| Newcastle, Kwa Zulu-Natal, South Africa, 2940 | |
| South Africa, KwaZulu Natal | |
| Durban, KwaZulu Natal, South Africa, 4091 | |
| Durban, KwaZulu Natal, South Africa, 4037 | |
| Spain | |
| Alicante, Spain, 03010 | |
| Barcelona, Spain, 08034 | |
| Valencia, Spain, 46010 | |
| Spain, Barcelona | |
| La Roca del Vallès, Barcelona, Spain, 08430 | |
| Spain, Cataluña | |
| Barcelona, Cataluña, Spain, 08025 | |
| Spain, Pontevedra | |
| Vigo, Pontevedra, Spain, 36211 | |
| Spain, Tenerife | |
| La Laguna, Tenerife, Spain, 38320 | |
| Study Director: | Bayer Study Director | Bayer |
More Information
| Responsible Party: | Bayer Schering Pharma AG ( Medical Affairs Therapeutic Area Head ) |
| Study ID Numbers: | 12146, EudraCT 2006-001228-37 |
| Study First Received: | September 8, 2006 |
| Last Updated: | November 7, 2008 |
| ClinicalTrials.gov Identifier: | NCT00377793 History of Changes |
| Health Authority: | Spain: Spanish Agency of Medicines; Germany: Federal Institute for Drugs and Medical Devices |
|
Sexual Dysfunctions, Psychological Phosphodiesterase Inhibitors Vardenafil Sexual Dysfunction, Physiological Molecular Mechanisms of Pharmacological Action Mental Disorders |
Enzyme Inhibitors Genital Diseases, Male Sexual and Gender Disorders Erectile Dysfunction Pharmacologic Actions |